ICCM

IceCure Medical Ltd (ICCM) 10Y Growth Potential Analysis (2026)

Invetso Score: 3/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 3.1 (Weak)

No reported 5-year revenue CAGR limits evidence of durable top-line compounding, while peers with disclosed growth histories can better demonstrate repeatable expansion.

Very high R&D intensity at 2.1x revenue suggests heavy reinvestment, but it has not yet translated into proven revenue scaling versus peers.

Low capex-to-revenue indicates limited asset expansion needs, yet that also implies the current model has not shown scalable commercial throughput.

Negative ROIC signals that incremental investment has not produced efficient growth, leaving ICCM behind peers that convert capital into sustained revenue expansion.

Market Tailwinds

Score:

No disclosed segment concentration or market-share data prevents evidence of a scalable demand engine, unlike peers that can show repeatable category penetration.

The company’s growth case is not supported by visible multi-year demand acceleration, so tailwinds remain unproven relative to better-positioned peers.

High cash conversion cycle of 170 days suggests working-capital drag, which can slow reinvestment into growth compared with more efficient peers.

Negative interest coverage indicates financial strain, reducing flexibility to fund expansion when peers with stronger coverage can reinvest more consistently.

Scalability Expansion

Score:

R&D spending is substantial, but the absence of demonstrated revenue conversion means the platform has not yet shown scalable monetization versus peers.

Net debt to EBITDA is modest, yet weak earnings quality limits the practical benefit of balance-sheet capacity for long-term expansion.

Capex intensity is low, which can support scalability, but the lack of proven growth output suggests underutilized operating leverage versus peers.

The current profile shows more investment burden than expansion efficiency, leaving ICCM structurally behind scalable peers with clearer compounding evidence.

Constraints Limitations

Score:

Negative ROIC indicates capital is not compounding effectively, which structurally caps long-term growth capacity unless execution improves materially versus peers.

A very long cash conversion cycle ties up liquidity, limiting reinvestment speed and reducing the company’s ability to scale faster than peers.

Negative interest coverage suggests financing stress, which can constrain growth funding and make expansion less durable than for stronger peers.

Missing historical growth disclosure and weak profitability together reduce visibility into sustained compounding, keeping the long-term growth profile constrained.

Overall Score

Score:

ICCM shows limited evidence of durable, scalable revenue compounding, and its heavy R&D burden has not yet translated into peer-competitive growth efficiency.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on IceCure Medical Ltd. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →